scholarly journals Evidence-Based Pharmacotherapy for Pediatric Obsessive-Compulsive Disorder and Chronic Tic Disorders

2011 ◽  
Vol 3 ◽  
pp. JCNSD.S6616 ◽  
Author(s):  
Alessandro S. De Nadai ◽  
Eric A. Storch ◽  
Joseph F. Mcguire ◽  
Adam B. Lewin ◽  
Tanya K. Murphy
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Psychosocial Interventions ◽  
Evidence Base ◽  
Tic Disorders ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
Behavioral Healthcare ◽  
Pediatric Ocd ◽  
Chronic Tic Disorders

In recent years, much progress has been made in pharmacotherapy for pediatric obsessive-compulsive disorder (OCD) and chronic tic disorders (CTDs). What were previously considered relatively intractable conditions now have an array of efficacious medicinal (and psychosocial) interventions available at clinicians' disposal, including selective serotonin reuptake inhibitors, atypical antipsychotics, and alpha-2 agonists. The purpose of this review is to discuss the evidence base for pharmacotherapy with pediatric OCD and CTDs with regard to efficacy, tolerability, and safety, and to put this evidence in the context of clinical management in integrated behavioral healthcare. While there is no single panacea for these disorders, there are a variety of medications that provide considerable relief for children with these disabling conditions.

Cohort profile: Epidemiology and Genetics of Obsessive–compulsive disorder and chronic tic disorders in Sweden (EGOS)

2020 ◽  
Vol 55 (10) ◽  
pp. 1383-1393 ◽  
Author(s):  
Behrang Mahjani ◽  
Karin Dellenvall ◽  
Anna-Carin Säll Grahnat ◽  
Gun Karlsson ◽  
Aki Tuuliainen ◽  
...  
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Tic Disorders ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
Chronic Tic Disorders

scholarly journals Cross-disorder comparison of sensory over-responsivity in chronic tic disorders and obsessive-compulsive disorder

2021 ◽  
pp. 152291
Author(s):  
David Isaacs ◽  
Alexandra P. Key ◽  
Carissa J. Cascio ◽  
Alexander C. Conley ◽  
Heather Riordan ◽  
...  
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Tic Disorders ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
Chronic Tic Disorders

Pharmacological management of comorbid obsessive–compulsive disorder and chronic non-affective psychosis

2020 ◽  
pp. 1-13
Author(s):  
Itoro Udo ◽  
Carol McDaniel ◽  
Chidi Chima
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Evidence Base ◽  
Behavioural Therapy ◽  
Current Evidence ◽  
Obsessive Compulsive ◽  
Pharmacological Management ◽  
Targeted Interventions ◽  
Compulsive Disorder ◽  
Before And After

SUMMARY The comorbidity of obsessive–compulsive symptoms (OCS) in the context of schizophrenia is often not recognised by clinicians, and patients may not report these symptoms until they become severe. However, there is a reported prevalence of 10–24% for obsessive–compulsive disorder (OCD) in schizophrenia and related disorders. The onset of OCS/OCD has been noted to occur both before and after the diagnosis of schizophrenia or schizoaffective disorder. It has also been known to occur following commencement of treatment with antipsychotic medications, especially clozapine. Current literature provides limited guidance for treatment. Review of the current evidence supports: addition of selective serotonin reuptake inhibitors (SSRIs) to antipsychotics; addition of aripiprazole, amisulpride or lamotrigine; or reduction in the dosage of clozapine. There is also evidence supporting the addition of cognitive–behavioural therapy and electroconvulsive therapy (ECT). The SSRIs that are evidenced to be useful are fluvoxamine, escitalopram, sertraline and paroxetine. More studies are needed to expand the evidence base. Early targeted interventions are recommended.

scholarly journals Translational neuroimaging research in pediatric obsessive-compulsive disorder

2010 ◽  
Vol 12 (2) ◽  
pp. 165-174 ◽  
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Psychiatric Illness ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Public Health Problem ◽  
Obsessive Compulsive ◽  
Compulsive Disorder ◽  
Pediatric Ocd ◽  
Significant Public Health Problem ◽  
Significant Public Health ◽  
Traditional Strategy

Obsessive-compulsive disorder (OCD) is a significant public health problem. Selective serotonin reuptake inhibitors (SSRIs) are the only FDA-approved medications for OCD. However, SSRIs are of limited efficacy in clinical practice. Given the persistence of symptoms and levels of treatment response, it is clear that the serotonin paradigm of OCD does not fully account for the neurobiology of the disorder, and that further translational research is needed. In this review, the glutamate hypothesis of pediatric OCD is explored, the neuroimaging evidence reviewed, and the translational impact highlighted. The traditional strategy of going from pharmacology to pathophysiology has failed to show real progress in our understanding of the neurobiology of psychiatric illness and, while still in the early stages, this work demonstrates the clear benefit of approaching psychiatric illness from the opposite direction.

Bipolar disorder and comorbid obsessive-compulsive disorder is associated with higher rates of anxiety and impulse control disorders

2010 ◽  
Vol 22 (2) ◽  
pp. 81-86 ◽  
Author(s):  
Cilly Klüger Issler ◽  
Emel Serap Monkul ◽  
José Antonio de Mello Siqueira Amaral ◽  
Renata Sayuri Tamada ◽  
Roseli Gedanke Shavitt ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Obsessive Compulsive Disorder ◽  
Impulse Control ◽  
Severe Form ◽  
Impulse Control Disorders ◽  
Tic Disorders ◽  
Obsessive Compulsive ◽  
Residual Symptoms ◽  
Compulsive Disorder ◽  
Depressive Episodes

Issler CK, Monkul ES, Amaral JAMS, Tamada RS, Shavitt RG, Miguel EC, Lafer B. Bipolar disorder and comorbid obsessive-compulsive disorder is associated with higher rates of anxiety and impulse control disorders.Objective:Although bipolar disorder (BD) with comorbid obsessive-compulsive disorder (OCD) is highly prevalent, few controlled studies have assessed this comorbidity. The objective of this study was to investigate the clinical characteristics and expression of comorbid disorders in female BD patients with OCD.Method:We assessed clinically stable female outpatients with BD: 15 with comorbid OCD (BD+OCD group) and 15 without (BD/no-OCD group). All were submitted to the Structured Clinical Interview for DSM-IV, with additional modules for the diagnosis of kleptomania, trichotillomania, pathological gambling, onychophagia and skin picking.Results:The BD+OCD patients presented more chronic episodes, residual symptoms and previous depressive episodes than the BD/no-OCD patients. Of the BD+OCD patients, 86% had a history of treatment-emergent mania, compared with only 40% of the BD/no-OCD patients. The following were more prevalent in the BD+OCD patients than the BD/no-OCD patients: any anxiety disorder other than OCD; impulse control disorders; eating disorders; and tic disorders.Conclusion:Female BD patients with OCD may represent a more severe form of disorder than those without OCD, having more depressive episodes and residual symptoms, and being at a higher risk for treatment-emergent mania, as well as presenting a greater anxiety and impulse control disorder burden.

Sign in / Sign up

Export Citation Format

Share Document